Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection

Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection

Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases. In 2015, edaravone was approved in Japan to tr...

Detaylı Bibliyografya
Asıl Yazarlar:	Sun Joo Cha, Kiyoung Kim
Materyal Türü:	Makale
Dil:	English
Baskı/Yayın Bilgisi:	MDPI AG 2022-01-01
Seri Bilgileri:	Antioxidants
Konular:	edaravone oxidative stress antioxidant mitochondria neurodegenerative disease amyotrophic lateral sclerosis
Online Erişim:	https://www.mdpi.com/2076-3921/11/2/195

Benzer Materyaller

A New Treatment Option for Amyotrophic Lateral Sclerosis: Edaravone
Yazar:: Erdi Şahin
Baskı/Yayın Bilgisi: (2018-03-01)

Edaravone: A new hope for patients with amyotrophic lateral sclerosis
Yazar:: Shivangi Garg, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
Yazar:: Hideki Houzen, ve diğerleri
Baskı/Yayın Bilgisi: (2021-07-01)

Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
Yazar:: Jin-Mo Park, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis
Yazar:: Chang Liu, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone
Yazar:: Hee Jo Han, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments
Yazar:: Maria A. Lapshina, ve diğerleri
Baskı/Yayın Bilgisi: (2023-11-01)

Bulbar Onset Amyotrophic Lateral Sclerosis: A Case Report
Yazar:: Kabindra Rai, ve diğerleri
Baskı/Yayın Bilgisi: (2023-02-01)

The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis
Yazar:: Jiantao Zhao, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Recent Advances on the Role of GSK3β in the Pathogenesis of Amyotrophic Lateral Sclerosis
Yazar:: Hyun-Jun Choi, ve diğerleri
Baskı/Yayın Bilgisi: (2020-09-01)

Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis
Yazar:: Benjamin Rix Brooks, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Iranian clinical practice guideline for amyotrophic lateral sclerosis
Yazar:: Reza Boostani, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Amyotrophic lateral sclerosis – aetiology, diagnostics and multidirectional, team, long-term care
Yazar:: Kamila Tuzim, ve diğerleri
Baskı/Yayın Bilgisi: (2018-08-01)

Amyotrophic lateral sclerosis – aetiology, diagnostics and multidirectional, team, long-term care
Yazar:: Kamila Tuzim, ve diğerleri
Baskı/Yayın Bilgisi: (2018-08-01)

The Protective Effect of Edaravone on TDP-43 Plus Oxidative Stress-Induced Neurotoxicity in Neuronal Cells: Analysis of Its Neuroprotective Mechanisms Using RNA Sequencing
Yazar:: Aki Soejima-Kusunoki, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Amyotrophic lateral sclerosis with frontotemporal dementia
Yazar:: Corina Roman-Filip, ve diğerleri
Baskı/Yayın Bilgisi: (2010-09-01)

Synthesis and Characterization of Edaravone Analogues as Remyelinating Agents and Putative Mechanistic Probes
Yazar:: Eleonora Colombo, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Advancements and challenges in amyotrophic lateral sclerosis
Yazar:: David Bradford, ve diğerleri
Baskı/Yayın Bilgisi: (2024-05-01)

Intestinal Microbiota and Sclerosis Lateral Amyotrophic
Yazar:: Mariana Dantas de Carvalho Vilar, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

The implications of DNA methylation for amyotrophic lateral sclerosis
Yazar:: ADRIANA HELENA DE OLIVEIRA REIS, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

The role of statins in amyotrophic lateral sclerosis: protective or not?
Yazar:: Hayder M. Al-kuraishy, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Evaluation of Sensory Nerve Conduction Abnormalities in Patients with Amyotrophic Lateral Sclerosis
Yazar:: Waseem H. Alkhaffaf
Baskı/Yayın Bilgisi: (2021-06-01)

New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis
Yazar:: Frances Theunissen, ve diğerleri
Baskı/Yayın Bilgisi: (2021-11-01)

Pre-Clinical Pharmacokinetic Characterization, Tissue Distribution, and Excretion Studies of Novel Edaravone Oral Prodrug, TEJ-1704
Yazar:: Dong Wook Kang, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

Prevalence of amyotrophic lateral sclerosis in Latium region, Italy
Yazar:: Maria Puopolo, ve diğerleri
Baskı/Yayın Bilgisi: (2021-12-01)

Mechanistic Insights of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis: An Update on a Lasting Relationship
Yazar:: Niccolò Candelise, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

Progress in the study of mitochondrial dysfunction in pathogenesis of amyotrophic lateral sclerosis
Yazar:: LIU Liyang, LIU Qing, LIU Yaping, ZHANG Xue
Baskı/Yayın Bilgisi: (2023-02-01)

Amyotrophic lateral sclerosis: pathogenetic mechanisms and new approaches to pharmacotherapy (literature review)
Yazar:: T. M. Alekseeva, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

Commentary: Urinary Neopterin, a New Marker of the Neuroinflammatory Status in Amyotrophic Lateral Sclerosis
Yazar:: Gisele Espíndola, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01)

Assessment of therapeutic response of edaravone and riluzole combination therapy in amyotrophic lateral sclerosis patients
Yazar:: Swapnil Samadhiya, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Oligodendrocytes in amyotrophic lateral sclerosis and frontotemporal dementia: the new players on stage
Yazar:: Marguerite Jamet, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

Biomarkers of Amyotrophic Lateral Sclerosis: Current Status and Interest of Oxysterols and Phytosterols
Yazar:: Anne Vejux, ve diğerleri
Baskı/Yayın Bilgisi: (2018-01-01)

The Cell Autonomous and Non-Cell Autonomous Aspects of Neuronal Vulnerability and Resilience in Amyotrophic Lateral Sclerosis
Yazar:: Christoph Schweingruber, ve diğerleri
Baskı/Yayın Bilgisi: (2022-08-01)

Evaluation of Peripheral Immune Activation in Amyotrophic Lateral Sclerosis
Yazar:: Mengli Wang, ve diğerleri
Baskı/Yayın Bilgisi: (2021-06-01)

Depression in amyotrophic lateral sclerosis
Yazar:: Joanna Iłżecka
Baskı/Yayın Bilgisi: (2021-10-01)

Amyotrophic lateral sclerosis : advances and perspectives of neuronanomedicine /
Yazar:: Machtoub, Lina, author, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
Yazar:: HaEun Cho, ve diğerleri
Baskı/Yayın Bilgisi: (2020-12-01)

Staging model for amyotrophic lateral sclerosis in Singapore
Yazar:: Yuan Teck Tay, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Analysis of SOD1 and C9orf72 mutations in patients with amyotrophic lateral sclerosis in Antioquia, Colombia
Yazar:: Jimena Jaramillo, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

Pain in Amyotrophic Lateral Sclerosis Is Underrated
Yazar:: Soyoung Kwak, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)